A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects.
about
Profile of bosutinib and its clinical potential in the treatment of chronic myeloid leukemiaEuropean LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemiaClinical advances in the management of chronic myelogenous leukemia: focus on bosutinib and patient considerationsBosutinib: a second-generation tyrosine kinase inhibitor for chronic myelogenous leukemia.The tyrosine kinase inhibitor dasatinib induces a marked adipogenic differentiation of human multipotent mesenchymal stromal cells.Drug monographs: bosutinib and regorafenib.Clinical pharmacology of tyrosine kinase inhibitors becoming generic drugs: the regulatory perspectiveBosutinib in the management of chronic myelogenous leukemia.Bosutinib: a SRC-ABL tyrosine kinase inhibitor for treatment of chronic myeloid leukemia.Bosutinib: a review of its use in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.Bosutinib : a review of preclinical and clinical studies in chronic myelogenous leukemia.Bosutinib: a novel src/abl kinase inhibitor for chronic myelogenous leukemia.Clinical Pharmacokinetics and Pharmacodynamics of Bosutinib.Bosutinib for Chronic Myeloid Leukemia.Bosutinib treatment for Philadelphia chromosome-positive leukemias.Effect of bosutinib on the absorption of dabigatran etexilate mesylate, a P-glycoprotein substrate, in healthy subjects.Bosutinib versus Placebo for Autosomal Dominant Polycystic Kidney Disease.A quantitative method for the determination of bosutinib in human plasma using high-performance liquid chromatography and ultraviolet detection.Practical Management of Toxicities Associated With Bosutinib in Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia.Absolute Bioavailability of Bosutinib in Healthy Subjects From an Open-Label, Randomized, 2-Period Crossover Study.Effects of meal type on the oral bioavailability of the ALK inhibitor ceritinib in healthy adult subjects.A clinical study to examine the potential effect of lansoprazole on the pharmacokinetics of bosutinib when administered concomitantly to healthy subjects.Effect of aprepitant, a moderate CYP3A4 inhibitor, on bosutinib exposure in healthy subjects.Correlation of plasma concentration and adverse effects of bosutinib: standard dose or dose-escalation regimens of bosutinib treatment for patients with chronic myeloid leukemia.Bosutinib: a third generation tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.Evaluation of the pharmacokinetics and safety of bosutinib in patients with chronic hepatic impairment and matched healthy subjects.
P2860
Q24607114-EDEB4E77-7BF9-4C4A-AA90-23AB65C66FD2Q26749324-D8011AB7-BAF4-48C5-96D8-2914C7195008Q27004032-1BF8D4B8-3C7B-4FCD-BCC5-F8033FEC95CBQ33412495-5FE0362B-52C6-433A-B7E5-CBC1642F7857Q34099289-137A9796-458F-464F-9084-4B8AA1ED639CQ37340111-F6A58A91-2717-4B5E-A094-520FF6F19D0FQ37580148-0DC6A177-765E-484F-B18B-AB06D772BCB0Q38106952-B37558DA-D28E-4946-A5A3-BE889A80D5E1Q38135813-3D772D3B-421E-4E7E-B8C0-172D4C54ED60Q38178192-F49C4634-390B-43E3-8F59-717FED750A39Q38183422-9BDEF30C-C396-4775-90F3-1AA0FFBB62A6Q38230432-ED8DC67F-DDD9-4111-BEF0-75DE321A6E82Q38817367-B2A4C08C-A976-4D9F-97DD-A604EE4CC9BAQ38835127-16E68E2F-FDE5-495C-AE6D-CC0F919A9D33Q39257678-C1D64727-A9A6-48D0-A004-3D7DE437A9A0Q39310587-F4F65651-4C61-46BD-B0B4-C0C158AD0A7CQ46220838-FF28A4C9-2CDA-4D1A-B436-CD9CDEFCD66BQ48324100-26223935-F82D-4121-BAA4-72C8656282CCQ49553324-C0DB7BB7-ED65-4643-8133-CE498B2766CDQ50068063-FEEEB78F-BA1C-4608-BC1F-4C76AD519124Q51298596-637EB729-5497-4B0B-B1B0-D42531C3EE50Q51337867-AE3D30AC-8842-4049-AC7F-BDAF7013AE4DQ51415497-531CBDA4-28D8-4A5E-9D91-E91A3CDD1940Q52571134-63E22781-1C2C-46FD-8E9A-A7BE1D1188AAQ54349085-A0B52FE1-A8E6-45C9-AF41-F845F204E505Q54478532-DC6BB548-E65A-4282-A5DF-ADBF5D38611F
P2860
A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
A phase I ascending single-dos ...... 06) in healthy adult subjects.
@en
A phase I ascending single-dos ...... 06) in healthy adult subjects.
@nl
type
label
A phase I ascending single-dos ...... 06) in healthy adult subjects.
@en
A phase I ascending single-dos ...... 06) in healthy adult subjects.
@nl
prefLabel
A phase I ascending single-dos ...... 06) in healthy adult subjects.
@en
A phase I ascending single-dos ...... 06) in healthy adult subjects.
@nl
P2093
P2860
P1476
A phase I ascending single-dos ...... 06) in healthy adult subjects.
@en
P2093
Bruce A Hug
Cathie Leister
Daryl Sonnichsen
Myriam El Gaaloul
Richat Abbas
Stephan Chalon
P2860
P2888
P304
P356
10.1007/S00280-011-1688-7
P577
2011-06-21T00:00:00Z